Pharmaceutical giants Johnson & Johnson and Sanofi have stopped a late-stage clinical trial for their experimental E.coli vaccine after results failed to demonstrate sufficient efficacy.

Sanofi ( (SNY)) has provided an announcement. On February 13, 2025, Sanofi announced the discontinuation of the E.mbrace phase 3 study for its extraintestinal pathogenic E. coli vaccine, following ...

Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn’t demonstrate ...

Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial.

The vaccine, currently in phase 3 trials, targets extraintestinal pathogenic Escherichia coli or ‘ExPEC’, which is estimated to cause around 10 million cases of invasive disease every year and ...

Sanofi and Johnson & Johnson are ending a Phase 3 study of an experimental E. coli vaccine after it failed to show a significant benefit over placebo in a review by an independent monitoring board.

a rHEV vaccine expressed in E. coli (23 kDa and HEV 239 vaccine), a rHEV vaccine expressed in insect Sf9 cells via recombinant baculovirus (56 kDa), a rHEV-VLP vaccine with oral administration (50 ...

have discontinued the E.mbrace phase 3 study evaluating a vaccine candidate for extraintestinal pathogenic E. coli. The E.mbrace study is a randomized, double-blind, placebo-controlled ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

This new system will aid researchers in developing vaccines and in studying the pathogenesis ... The modified genomes are then transferred to E. coli, which makes isolating them in larger amounts ...

E. coli bacteria could be used to create biodegradable plastics, reports a paper published in Nature Chemical Biology. The ...